Marko Lens

Summary

Publications

  1. ncbi Use of fullerenes in cosmetics
    Marko Lens
    King s College, Genetic Epidemiology Unit, St Thomas s Hospital, Lambeth Palace Road, London, UK
    Recent Pat Biotechnol 3:118-23. 2009
  2. ncbi Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials
    Marko B Lens
    Center for Evidence Based Medicine, University of Oxford, Oxford, United Kingdom
    J Clin Oncol 20:1818-25. 2002
  3. ncbi Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease
    Marko Lens
    Imperial College, Department of Epidemiology and Public Health, Faculty of Medicine, St Mary s Campus, Norfolk Place, London, England
    Dermatol Ther 19:9-18. 2006
  4. ncbi Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials
    Marko B Lens
    King s College, Genetic Epidemiology Unit, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, England
    Arch Surg 142:885-91; discussion 891-3. 2007
  5. ncbi Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues
    Marko Lens
    Twin Research and Genetic Epidemiology Unit, King s College London, St Thomas Hospital Campus, Lambeth Palace Road, London, SE1 7EH, UK
    Cancer Causes Control 19:437-42. 2008
  6. ncbi Antioxidative capacity of C(60) (buckminsterfullerene) and newly synthesized fulleropyrrolidine derivatives encapsulated in liposomes
    Marko Lens
    King s College, Genetic Epidemiology Unit, St Thomas Hospital, Lambeth Palace Road, London SE17EH, UK
    Biotechnol Appl Biochem 51:135-40. 2008
  7. ncbi The role of vaccine therapy in the treatment of melanoma
    Marko Lens
    King s College, St Thomas Hospital, Genetic Epidemiology Unit, Lambeth Palace Road, London SE1 7EH, UK
    Expert Opin Biol Ther 8:315-23. 2008
  8. ncbi Systemic retinoids in chemoprevention of non-melanoma skin cancer
    Marko Lens
    St Thomas Hospital, King s College, Genetic Epidemiology Unit, Lambeth Palace Road, London SE1 7EH, UK
    Expert Opin Pharmacother 9:1363-74. 2008
  9. ncbi Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings
    Marko Lens
    King s College, Genetic Epidemiology Unit, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Recent Pat Anticancer Drug Discov 3:105-13. 2008
  10. ncbi p53 labeling index in assessing the efficacy of a sunscreen in protection against UV-induced damage
    Marko Lens
    Twin Research and Genetic Epidemiology Unit, King s College, London, UK
    Int J Dermatol 47:1234-9. 2008

Collaborators

Detail Information

Publications32

  1. ncbi Use of fullerenes in cosmetics
    Marko Lens
    King s College, Genetic Epidemiology Unit, St Thomas s Hospital, Lambeth Palace Road, London, UK
    Recent Pat Biotechnol 3:118-23. 2009
    ..Future trends in the development of cosmetic formulations including fullerenes are discussed...
  2. ncbi Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials
    Marko B Lens
    Center for Evidence Based Medicine, University of Oxford, Oxford, United Kingdom
    J Clin Oncol 20:1818-25. 2002
    ..The effect of interferon alfa (IFNalpha) as a single agent or in combination has been widely explored in clinical trials. The purpose of this study was to assess the benefit of IFNalpha therapy in malignant melanoma...
  3. ncbi Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease
    Marko Lens
    Imperial College, Department of Epidemiology and Public Health, Faculty of Medicine, St Mary s Campus, Norfolk Place, London, England
    Dermatol Ther 19:9-18. 2006
    ..Results from ongoing studies are awaited. Further research for this therapy is required...
  4. ncbi Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials
    Marko B Lens
    King s College, Genetic Epidemiology Unit, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, England
    Arch Surg 142:885-91; discussion 891-3. 2007
    ..To determine the effectiveness of wide vs narrow excision margins in the treatment of primary cutaneous melanoma...
  5. ncbi Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues
    Marko Lens
    Twin Research and Genetic Epidemiology Unit, King s College London, St Thomas Hospital Campus, Lambeth Palace Road, London, SE1 7EH, UK
    Cancer Causes Control 19:437-42. 2008
    ..About one third of all melanoma in women occur during their childbearing age. An association between melanoma and hormonal and reproductive factors remains controversial...
  6. ncbi Antioxidative capacity of C(60) (buckminsterfullerene) and newly synthesized fulleropyrrolidine derivatives encapsulated in liposomes
    Marko Lens
    King s College, Genetic Epidemiology Unit, St Thomas Hospital, Lambeth Palace Road, London SE17EH, UK
    Biotechnol Appl Biochem 51:135-40. 2008
    ..However, further research is required to establish the toxicity of these derivatives and their antioxidant efficacy in vivo...
  7. ncbi The role of vaccine therapy in the treatment of melanoma
    Marko Lens
    King s College, St Thomas Hospital, Genetic Epidemiology Unit, Lambeth Palace Road, London SE1 7EH, UK
    Expert Opin Biol Ther 8:315-23. 2008
    ..Since it has been considered to be a highly immunogenic tumour, it has become an excellent target for the active specific immunotherapy. Vaccine therapy represents a novel approach to the treatment of melanoma...
  8. ncbi Systemic retinoids in chemoprevention of non-melanoma skin cancer
    Marko Lens
    St Thomas Hospital, King s College, Genetic Epidemiology Unit, Lambeth Palace Road, London SE1 7EH, UK
    Expert Opin Pharmacother 9:1363-74. 2008
    ..Systemic retinoids are useful for the chemoprophylaxis of non-melanoma skin cancers. Retinoids have pleiotropic effects, but their exact cancer chemopreventive mechanism is still not clear...
  9. ncbi Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings
    Marko Lens
    King s College, Genetic Epidemiology Unit, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Recent Pat Anticancer Drug Discov 3:105-13. 2008
    ..Several phase II/III trials are ongoing to evaluate ipilimumab alone or in combination with other therapeutic modalities. Results from these trials are awaited...
  10. ncbi p53 labeling index in assessing the efficacy of a sunscreen in protection against UV-induced damage
    Marko Lens
    Twin Research and Genetic Epidemiology Unit, King s College, London, UK
    Int J Dermatol 47:1234-9. 2008
    ..Our objective was to determine the role of the p53 labeling index in assessing the effectiveness of a sunscreen in the prevention of UV-induced DNA damage...
  11. ncbi Sentinel lymph node biopsy in melanoma patients
    M Lens
    Genetic Epidemiology Unit, King s College, St Thomas Hospital, London, UK
    J Eur Acad Dermatol Venereol 24:1005-12. 2010
    ..Large-scale ongoing randomized trials should elucidate whether SLNB with complete lymphadenectomy has a survival benefit in melanoma patients with early lymph node metastases compared to 'watch-and-wait' policy (observation)...
  12. ncbi Assessment of the kinetics of the antioxidative capacity of topical antioxidants
    Marko Lens
    King s College, Genetic Epidemiology Unit, St Thomas Hospital, United Kingdom
    J Drugs Dermatol 10:262-7. 2011
    ..0001). Determination of the kinetics of squalene peroxidation is a reliable in vivo method in the evaluation of antioxidant capacity of cosmetic formulations...
  13. ncbi Recent progresses in application of fullerenes in cosmetics
    Marko Lens
    King s College, St Thomas s Hospital, Westminster Bridge Road, London SE1 7EH, UK
    Recent Pat Biotechnol 5:67-73. 2011
    ..Recent trends in the use of fullerenes in topical formulations and patents are reviewed. Future investigations covering application of fullerenes in skin care are discussed...
  14. ncbi Desmoplastic malignant melanoma: a systematic review
    M B Lens
    Genetic Epidemiology Division, Cancer Research UK, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Br J Dermatol 152:673-8. 2005
    ..Desmoplastic melanoma (DM) is an uncommonly encountered type of malignant melanoma. The clinical appearance of DM can be highly variable and thus, diagnosis of this tumour is difficult and very often may mislead the physician...
  15. ncbi An association between cutaneous melanoma and non-Hodgkin's lymphoma: pooled analysis of published data with a review
    M B Lens
    Genetic Epidemiology Division, Cancer Research UK, St James s University Hospital, Leeds, UK
    Ann Oncol 16:460-5. 2005
    ..Several epidemiological studies have suggested an association between cutaneous melanoma and non-Hodgkin's lymphoma...
  16. ncbi Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials
    Marko B Lens
    Centre for Evidence Based Medicine, University of Oxford Nuffield Department of Clinical Medicine, the Oxford Radcliffe National Health Service Trust, Oxford OX3 9DU, England
    Arch Surg 137:458-61. 2002
    ..Elective lymph node dissection does not improve survival in patients with melanoma without clinically detectable lymph node metastases...
  17. ncbi Economic evaluation in evidence-based practice
    Marko B Lens
    Centre for Evidence Based Medicine, University of Oxford, Department of Clinical Medicine, The Oxford Radcliffe NHS Trust, UK
    Expert Opin Pharmacother 3:1239-43. 2002
    ..The main types of economic analyses are described in this article, providing a framework along which to evaluate them...
  18. ncbi Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma
    Marko Lens
    King s College, Genetic Epidemiology Unit, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom
    Curr Top Med Chem 12:61-6. 2012
    ..Further research is necessary to elucidate role of ipilimumab in adjuvant setting as well as in synergy with other novel modalities for the treatment of metastatic melanoma...
  19. ncbi Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials
    Marko B Lens
    John Radcliffe Hospital at the University of Oxford, UK
    Lancet Oncol 4:359-64. 2003
    ....
  20. ncbi Use of tamoxifen in the treatment of malignant melanoma
    Marko B Lens
    University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer 98:1355-61. 2003
    ..The aim of the current study was to summarize the available clinical evidence on the role of the tamoxifen in different combination chemotherapy regimens because clinical studies including tamoxifen have produced inconclusive results...
  21. ncbi Systemic chemotherapy in the treatment of malignant melanoma
    Marko B Lens
    University of Oxford, CEBM, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Expert Opin Pharmacother 4:2205-11. 2003
    ..The use of classical systemic chemotherapy still has a role in the treatment of patients with metastatic melanoma. Immunotherapy and biochemotherapy have no additional advantage over chemotherapy...
  22. ncbi Effect of pregnancy on survival in women with cutaneous malignant melanoma
    Marko B Lens
    Genetic Epidemiology Division, Cancer Research UK, St James s University Hospital, Beckett St, Leeds LS9 7TF, UK
    J Clin Oncol 22:4369-75. 2004
    ..An adverse influence of pregnancy on the risk of death in women with cutaneous melanoma was suggested historically by anecdotal reports. Previous studies included small numbers of women observed for short periods...
  23. ncbi Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma
    M B Lens
    John Radcliffe Hospital, University of Oxford, Oxford, UK
    Br J Dermatol 150:179-85. 2004
    ..Trends in melanoma incidence worldwide are examined. The most recent data on the mortality from cutaneous melanoma are reported. The role of different environmental, genetic and host factors in the aetiology of melanoma is discussed...
  24. ncbi Current clinical overview of cutaneous melanoma
    Marko Lens
    King s College, Genetic Epidemiology Unit, St Thomas s Hospital, London
    Br J Nurs 17:300-5. 2008
    ..Progresses in molecular biology and genetics of melanoma may lead to the development of novel melanoma therapies...
  25. ncbi Melanoma of the small intestine
    Marko Lens
    King s College, Genetic Epidemiology Unit, St Thomas s Hospital, London, UK
    Lancet Oncol 10:516-21. 2009
    ..Patients with primary melanoma of the small intestine have a worse prognosis than do patients with metastases of cutaneous melanoma...
  26. ncbi Novel and recurrent FERMT1 gene mutations in Kindler syndrome
    Tanasit Techanukul
    St John s Institute of Dermatology, King s College London, UK
    Acta Derm Venereol 91:267-70. 2011
    ..In the current study, we describe five novel and three recurrent loss-of-function FERMT1 mutations in eight individuals with Kindler syndrome, and provide an overview of genotype-phenotype correlation in this disorder...
  27. ncbi Pigmentation and vitamin D metabolism in Caucasians: low vitamin D serum levels in fair skin types in the UK
    Daniel Glass
    Department of Twin Research and Genetic Epidemiology, Kings College London, St Thomas Hospital Campus, London, UK
    PLoS ONE 4:e6477. 2009
    ..Public health messages are advocating sun avoidance to reduce skin cancer risk but the potential deleterious effects of these recommendations for vitamin D metabolism have been poorly investigated...
  28. ncbi Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy
    M B Lens
    University of Oxford, Centre for Evidence-based Medicine, Nuffield Department of Clinical Medicine and Department for Plastic and Reconstructive Surgery, The Oxford Radcliffe NHS Trust, Oxford, UK
    Br J Surg 89:1223-7. 2002
    ..CONCLUSION: The Breslow thickness of primary melanoma predicts the presence of a sentinel node metastasis. The published data are not sufficient to demonstrate a correlation between other known prognostic indicators and a positive SLNB...
  29. ncbi Management of regional lymph nodes in patients with malignant melanoma: questionnaire survey of UK current practice
    M B Lens
    Centre for Evidence-Based Medicine and Department for Plastic and Reconstructive Surgery, University of Oxford, Oxford, UK
    Br J Plast Surg 55:372-5. 2002
    ..On the basis of this current practice, we recommend the setting up of a prospective clinical melanoma register to record the surgical treatment of melanoma patients...
  30. ncbi Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision
    Marko B Lens
    Centre for Evidence-based Medicine, University of Oxford, Nuffield Department of Clinical Medicine, The Oxford Radcliffe NHS Trust, Oxford, England
    Arch Surg 137:1101-5. 2002
    ..However, current evidence is not sufficient to address the optimal surgical margins for all melanomas, and further research is required...
  31. ncbi The role of biological response modifiers in malignant melanoma
    Marko B Lens
    University of Oxford, John Radcliffe NHS Trust, Oxford, UK
    Expert Opin Biol Ther 3:1225-31. 2003
    ..Many toxic effects are induced by high-dose IL-2 therapy. Combinations of chemotherapy and biological response modifiers and their impact on tumour response and survival are discussed...
  32. ncbi Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick)
    Marko B Lens
    Cancer 100:433-4; author reply 434. 2004